| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/20/2011 | WO2011006983A1 Amino derivatives of dihydro-1,3,5-triazine for treating oxidative stress |
| 01/20/2011 | WO2011006803A1 3-0x0-2, 3, -dihydro-lh-isoindole-4-carboxamides with selective parp-1 inhibition |
| 01/20/2011 | WO2011006794A1 3-oxo-2, 3-dihydro-lh-isoindole-4-carboxamides as parp inhibitors |
| 01/20/2011 | WO2011006569A1 Heterocyclic compounds as autotaxin inhibitors |
| 01/20/2011 | WO2011006567A1 Aminopyridine derivatives for treating tumors and inflammatory diseases |
| 01/20/2011 | WO2011006273A1 Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases |
| 01/20/2011 | WO2011006226A1 Proteins, protease inhibiting peptides and derivatives thereof, medicinal, nutraceutical and cosmeceutical compositions based on these compounds, and uses thereof for preparing formulations for the treatment and prevention of cancer or diseases involving protease inhibition |
| 01/20/2011 | WO2010129918A8 Triptolide prodrugs |
| 01/20/2011 | WO2010120400A3 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors |
| 01/20/2011 | WO2010107658A3 Methods and compositions for bi-specific targeting of cd19/cd22 |
| 01/20/2011 | WO2010102286A3 Proteasome inhibitors having chymotrypsin-like activity |
| 01/20/2011 | WO2010062656A3 Deuterated 2-propylpentanoic acid compounds |
| 01/20/2011 | WO2010003475A8 Novel pyrrolidone derivatives for use as metap-2 inhibitors |
| 01/20/2011 | US20110016547 Use of regulatory sequences for specific, transient expression in neuronal determined cells |
| 01/20/2011 | US20110015663 Combination Therapies for the Treatment of Obesity |
| 01/20/2011 | US20110015437 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/20/2011 | US20110015395 Pyrazole compounds with inhibitory activity against ros kinase |
| 01/20/2011 | US20110015276 Therapeutical uses of inecalcitol |
| 01/20/2011 | US20110015263 Therapeutic delivery of carbon monoxide |
| 01/20/2011 | US20110015259 Tle3 as a marker for chemotherapy |
| 01/20/2011 | US20110015250 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 GENE |
| 01/20/2011 | US20110015249 Methods and compositions for treatment of cancer and other angiogenesis-related diseases |
| 01/20/2011 | US20110015248 Substituted heterocycles |
| 01/20/2011 | US20110015245 Bendamustine amphiphilic cationic compositions |
| 01/20/2011 | US20110015244 Bendamustine amphiphilic anionic compositions |
| 01/20/2011 | US20110015242 Pdk-1/akt signaling inhibitors |
| 01/20/2011 | US20110015240 Thiazole derivative and use thereof as vap-1 inhibitor |
| 01/20/2011 | US20110015228 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| 01/20/2011 | US20110015222 Benzoquinolizinium salt derivatives as anticancer agents |
| 01/20/2011 | US20110015221 Pharmaceutical composition of vinflunine which is intended for parenteral administration preparation method thereof and use of same |
| 01/20/2011 | US20110015219 (+)-Morphinans as Antagonists of Toll-Like Receptor 9 and Therapeutic Uses Thereof |
| 01/20/2011 | US20110015218 Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 01/20/2011 | US20110015214 Tricyclic benzo[4,5]thieno-[2,3-d]pyrimidine-4-yl-amin derivatives, their salts, process for producing the compounds and their pharmaceutical use |
| 01/20/2011 | US20110015212 Pyrimidinones as pi3k inhibitors |
| 01/20/2011 | US20110015211 Fibrosis inhibitor |
| 01/20/2011 | US20110015204 Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| 01/20/2011 | US20110015201 Hedgehog pathway antagonists and methods of use |
| 01/20/2011 | US20110015197 mTOR INHIBITOR SALT FORMS |
| 01/20/2011 | US20110015195 Aryl ureas with angiogenisis inhibiting activity |
| 01/20/2011 | US20110015187 Substituted heteroarylamide diazepinopyrimidone derivatives |
| 01/20/2011 | US20110015184 Vinyl-phenyl derivatives for inflammation and immune-related uses |
| 01/20/2011 | US20110015183 Substituted pyrazole sigma receptor antagonists |
| 01/20/2011 | US20110015177 Substituted arylamide oxazepinopyrimidone derivatives |
| 01/20/2011 | US20110015176 Substituted heteroarylamide oxazepinopyrimidone derivatives |
| 01/20/2011 | US20110015175 Bicyclic Compounds for the Reduction of Beta-Amyloid Production |
| 01/20/2011 | US20110015174 Cyclic inhibitors of carnitine palmitoyltransferase and treating cancer |
| 01/20/2011 | US20110015173 Pyrrolopyridine inhibitors of kinases |
| 01/20/2011 | US20110015172 Pyrrolopyrazine inhibitors of kinases |
| 01/20/2011 | US20110015161 Pharmaceutical containing a horomone combination having a contraceptive effecr and an insulin sensitizer |
| 01/20/2011 | US20110015145 Cladribine formulations for improved oral and transmucosal delivery |
| 01/20/2011 | US20110015144 Administration method proposing device |
| 01/20/2011 | US20110015141 Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
| 01/20/2011 | US20110015135 Antitumoral Treatments |
| 01/20/2011 | US20110015134 Method of treatment for early stage cancer |
| 01/20/2011 | US20110015133 Pax2 and pax8 as tumour targets for immunologic and molecular treatment strategies |
| 01/20/2011 | US20110015130 Polypeptides Selective for alphavbeta3 Integrin Conjugated With a Variant Of Human Serum Albumin (HSA) And Pharmaceutical Uses Thereof |
| 01/20/2011 | US20110015129 New paediatric indications for direct thrombin inhibitors |
| 01/20/2011 | US20110015126 Compositions and Methods For Inducing Apoptosis In Tumor Cells |
| 01/20/2011 | US20110014303 Method for the treatment of cancer |
| 01/20/2011 | US20110014302 Use of transplatin to prevent hearing loss |
| 01/20/2011 | US20110014281 Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| 01/20/2011 | US20110014264 Medical Devices Having Nanostructured Regions For Controlled Tissue Biocompatibility And Drug Delivery |
| 01/20/2011 | US20110014251 Microvesicles |
| 01/20/2011 | US20110014245 Therapeutic method of administering pharmaceutical titanium dioxide composite and light irradiation |
| 01/20/2011 | US20110014241 Therapeutic Cancer Antigens |
| 01/20/2011 | US20110014240 Single cycle replicating adenovirus vectors |
| 01/20/2011 | US20110014239 Preparation of Vaccines Using Photosensitizer and Light |
| 01/20/2011 | US20110014231 Anti-measles cancer immunotherapy |
| 01/20/2011 | US20110014229 Chimeric flavivirus vectors |
| 01/20/2011 | US20110014228 Il23 modified viral vector for recombinant vaccines and tumor treatment |
| 01/20/2011 | US20110014216 Drug Transfer Based on Coenzyme A and Acyl Carrier Protein |
| 01/20/2011 | US20110014214 Diagnostic and Therapeutic Utility of Tribbles-2 in Human Cancers |
| 01/20/2011 | US20110014207 Combination treatment for non-hematologic malignancies |
| 01/20/2011 | US20110014204 Cancer Chemoprevention Strategy Based on Loss of Imprinting of IGF2 |
| 01/20/2011 | US20110014202 Methods for Diagnosing and Treating Neuroendocrine Cancer |
| 01/20/2011 | US20110014198 Anti-vegf antibodies |
| 01/20/2011 | US20110014196 Drug Transfer into Living Cells |
| 01/20/2011 | US20110014195 Use of therapeutic peptides for the treatment and prevention of cancer |
| 01/20/2011 | US20110014194 Methods for inhibiting angiogenesis using egfl8 antagonists |
| 01/20/2011 | US20110014192 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators |
| 01/20/2011 | US20110014191 Breast cancer expression profiling |
| 01/20/2011 | US20110014189 Stable pharmaceutical composition comprising at least one monoclonal antibody and at least one amphiphilic polysaccharide comprising hydrophobic substituents |
| 01/20/2011 | US20110014186 Arylsulfonamide-based matrix metalloprotease inhibitors |
| 01/20/2011 | US20110014185 Methods involving graf polypeptides |
| 01/20/2011 | US20110014173 Axl tyrosine kinase inhibitors and methods of making and using the same |
| 01/20/2011 | US20110014169 High affinity ny-eso t cell receptors |
| 01/20/2011 | US20110014165 Thymidylate Kinase Mutants and Uses Thereof |
| 01/20/2011 | US20110014164 Efficient induction of pluripotent stem cells using small molecule compounds |
| 01/20/2011 | US20110014162 Preserved Compositions of Activated NK Cells and Methods of Using the Same |
| 01/20/2011 | US20110014155 Reovirus for the Treatment of Cellular Proliferative Disorders |
| 01/20/2011 | US20110014152 Increased t-cell tumor infiltration and eradication of metastases by mutant light |
| 01/20/2011 | US20110014137 Methods for protecting the skin from radiation insults |
| 01/20/2011 | US20110014128 Cytokine receptor modulators, method of identifying same, and method of modulating cytokine receptors activity with same |
| 01/20/2011 | US20110014123 RNA interference mediating small RNA molecules |
| 01/20/2011 | US20110014122 Novel anti-igf-ir and/or anti-insulin/igf-i hybrid receptors antibodies and uses thereof |
| 01/20/2011 | US20110014121 Modulators of cxcr7 |
| 01/20/2011 | US20110014120 Trifunctional imaging agent for monoclonal antibody tumor-targeted imaging |
| 01/20/2011 | US20110014118 Nanotherapeutic colloidal metal compositions and methods |
| 01/20/2011 | US20110014117 Anti-igf1r |
| 01/20/2011 | DE102010026686A1 Hemmung des Überlebens von Pankreaskrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of pancreatic cancer by cyclohexenone from Antrodia camphorata |